Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Generics Will Be Dispensed for No More Than 10% of Prescriptions: Dr Muto
March 3, 2008
- Need to Enhance R&D Ability of Medical Devices Industry Stressed
March 3, 2008
- TOPICS／Daiichi Sankyo Introduces Stock Compensation-Type Stock Option Plan
March 3, 2008
- NPhA Frustrated with Maintenance of 2 Different Dispensing Fees
March 3, 2008
- Japan's Most Admired Pharma Companies in 2007
March 3, 2008
- Study on Inhibition of Diabetic Progression to Start this Year
March 3, 2008
- Fusion of Technologies from FUJIFILM and Toyama to Enhance R&D
March 3, 2008
- Annual Limit of 25 Cases Proposed for CV Surgery Facilities
March 3, 2008
- Takeda, Merck Serono Drop Matuzumab due to Inefficacy
March 3, 2008
- Real Medical Institution Bankruptcy Crisis Yet to Come
March 3, 2008
- PIII Trial of Nexavar in NSCLC Discontinued: Bayer, Onyx
March 3, 2008
- Negative Opinions Include Fear of Clinical Trials: CMIC
March 3, 2008
- TOPICS／Pfizer Foundation Supports 2 Japanese NGOs to Fight Tobacco and Breast Cancer
March 3, 2008
- Daiichi Sankyo Places Top Priority on 5 Projects
March 3, 2008
- Sanofi-aventis Enters into Antibody Agreements with Dyax
March 3, 2008
- Blood Pressure Management Not Adequate: Pfizer Survey
March 3, 2008
- Toyobo Expands Contract Manufacturing Business
March 3, 2008
- NCCHD-Led NW to Participate in Multinational Clinical Trials
March 3, 2008
- Sales of Plavix Up 5.5-Fold in Japan: sanofi-aventis
March 3, 2008
- Development Delayed for 16 Unapproved Drugs
March 3, 2008
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…